MetaCap

Adlai Nortye Group Ltd. ADR (ANL)

NASDAQ: ANLHealth CareBiotechnology: Pharmaceutical PreparationsUSD

8.55-0.51 (-5.63%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ANL stock chart

Technical analysis

Key statistics

All statistics
Market cap
$550.60M
EPS (TTM)
-$0.66
52-week range
0.879 – 17.25
Day range
8.36 – 9.11
Volume / Avg
380.64K / 244.74K
Beta
—

52-week range

$0.879$17.25

ANL stock today

Adlai Nortye Group (ANL) closed at $8.55 on Nov 20, down 5.63% (-$0.51), versus the S&P 500's 3.70% decline. Shares are 50.4% below their 52-week high of $17.25, set on Apr 21, 2026 and 872.7% above the 52-week low of $0.879, in the middle of the past year's range. ANL is up 502.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 533.3%.

Adlai Nortye Group has posted a net loss over the last twelve months (EPS of -$0.66), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Adlai Nortye Group

Company profile

Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Yang Lu EMBA
Headquarters
Singapore
Employees
109
IPO year
2023

Financial highlights

Full financials

Adlai Nortye Group reported a net loss of $51.9 million, compared with a loss of $109.2 million a year earlier. Diluted earnings per share came in at -$0.54.

Adlai Nortye Group annual revenue, net income and EPS
Fiscal yearFY 2024FY 2023FY 2022FY 2021
Revenue—$5.00M—$45.73M
Growth————
Net income$-51.87M$-109.23M$-58.79M$-56.68M
EPS (diluted)$-0.54$-2.52$-2.31$-2.23

Analyst forecast

Forecast

Consensus (7 analysts)

strong_buy

Avg. price target

$29.50+245.03%

  • Strong buy 0
  • Buy 7
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $20.00High $49.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

ANL news

All ANL news

Adlai Nortye Group peers

Health Care sector
ANL peer companies
CompanyPrice% ChgMarket capCompare
ACRSAclaris Therapeutics Inc.3.44-1.71%$545.63Mvs ANL
AVBPArriVent BioPharma Inc.10.52-6.57%$544.13Mvs ANL
CBIOCrescent Biopharma Inc.13.00+0.70%$543.21Mvs ANL
BCAXBicara Therapeutics Inc.8.44-7.46%$560.31Mvs ANL
GERNGeron Corporation0.8707-4.63%$560.94Mvs ANL
CLYMClimb Bio Inc.9.19-0.97%$539.80Mvs ANL
DSGNDesign Therapeutics Inc.9.02-3.22%$577.61Mvs ANL
ZVRAZevra Therapeutics Inc.8.76-3.42%$521.26Mvs ANL

Indexes, lists and sector

Adlai Nortye Group stock FAQ

What is Adlai Nortye Group's stock price today?

ANL last traded at $8.55 as of Nov 20, 4:00 PM EST, down 5.63% on the day. Prices are delayed at least 15 minutes.

Who is Adlai Nortye Group's CEO?

Mr. Yang Lu EMBA is the chief executive officer of Adlai Nortye Group Ltd. ADR, which has about 109 employees.

What is the ANL 52-week high?

The 52-week high for ANL is $17.25 and the 52-week low is $0.879. The stock is currently 50.4% below its high.

Compare ANL